Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

Article  Google Scholar 

Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, et al. Epidemiology of liver metastases. Cancer Epidemiol. 2020;67:101760.

Article  PubMed  Google Scholar 

Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, et al. Personalized medicine: recent progress in cancer therapy. Cancers. 2020;12(4):1009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt KT, Chau CH, Price DK, Figg WD. Precision oncology medicine: the clinical relevance of patient-specific biomarkers used to optimize cancer treatment. J Clin Pharmacol. 2016;56(12):1484–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017 Oct 3;10:4821–4828. https://doi.org/10.2147/OTT.S140671

Houghton JL, Zeglis BM, Abdel-Atti D, Sawada R, Scholz WW, Lewis JS. Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses. J Nucl Med. 2016;57(3):453–9.

Article  CAS  PubMed  Google Scholar 

Rodriguez C, Delaney S, Sarrett SM, Keinänen OM, Zeglis BM. Antibody engineering for nuclear imaging and radioimmunotherapy. J Nucl Med. 2022;63(9):1316–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Koumna S, Pouliot F, Beauregard J-M, Kolinsky M. PSMA theranostics: current landscape and future outlook. Cancers. 2021;13(16):4023.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterology: WJG. 2014;20(12):3069.

Article  PubMed Central  Google Scholar 

Roth GS, Benhamou M, Teyssier Y, Seigneurin A, Abousalihac M, Sengel C, et al. Comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: a propensity score analysis. Cancers. 2021;13(4):812.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med. 2017;58(Supplement 2):S104–11.

Article  Google Scholar 

Nurili F, Monette S, Michel AO, Bendet A, Basturk O, Askan G, et al. Transarterial embolization of liver cancer in a transgenic pig model. J Vasc Interv Radiol. 2021;32(4):510–7. e3.

Article  PubMed  PubMed Central  Google Scholar 

Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078–88.

Article  CAS  PubMed  Google Scholar 

McCarthy JR. The future of theranostic nanoagents. Nanomedicine. 2009;4(7):693–5.

Article  PubMed  Google Scholar 

Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879–903.

Article  CAS  PubMed  Google Scholar 

Wilkes GM. Targeted therapy: attacking cancer with molecular and immunological targeted agents. Asia-Pacific J Oncol Nurs. 2018;5(2):137–55.

Article  Google Scholar 

Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96.

Article  CAS  PubMed  Google Scholar 

Liu JK. The history of monoclonal antibody development–progress, remaining challenges and future innovations. Annals Med Surg. 2014;3(4):113–6.

Article  Google Scholar 

Narsinh KH, Cui J, Papadatos D, Sirlin CB, Santillan CS. Hepatocarcinogenesis and Li-rads. Abdom Radiol. 2018;43:158–68.

Article  Google Scholar 

Spreafico C, Morosi C, Maccauro M, Romito R, Lanocita R, Civelli EM, et al. Intrahepatic flow redistribution in patients treated with radioembolization. Cardiovasc Interv Radiol. 2015;38:322–8.

Article  Google Scholar 

Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of 99m Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90 Y-loaded microspheres. Eur J Nucl Med Mol Imaging. 2016;43:559–75.

Article  CAS  PubMed  Google Scholar 

Roosen J, Klaassen NJ, Westlund Gotby LE, Overduin CG, Verheij M, Konijnenberg MW, et al. To 1000 gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. Eur J Nucl Med Mol Imaging. 2021;48:3776–90.

Article  PubMed  PubMed Central  Google Scholar 

Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The low hepatic toxicity per Gray of 90Y glass microspheres is linked to their transport in the arterial tree favoring a nonuniform trapping as observed in posttherapy PET imaging. J Nucl Med. 2014;55(1):135–40.

Article  CAS  PubMed  Google Scholar 

Pasciak AS, Abiola G, Liddell RP, Crookston N, Besharati S, Donahue D, et al. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure. Eur J Nucl Med Mol Imaging. 2020;47:816–27.

Article  CAS  PubMed  Google Scholar 

Ahmadzadehfar H. Targeted therapy for metastatic prostate cancer with radionuclides. Pro Cancer–Lead–Edge Diag Proc Treat. 2016;28:60–4.

Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [177 Lu] Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1473–9.

Article  CAS  PubMed  Google Scholar 

Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477.

Article  PubMed  PubMed Central  Google Scholar 

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, et al. Safety of multiple repeated cycles of 177 Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging. 2017;44:1207–14.

Article  CAS  PubMed  Google Scholar 

Ebbers SC, Barentsz MW, de Vries-Huizing DM, Versleijen MW, Klompenhouwer EG, Tesselaar ME, Stokkel MP, Brabander T, Hofland J, Moelker A, van Leeuwaarde RS. Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). European J Nuc Medi Mole Imag. 2024 Mar;51(4):1121–32.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-hodgkin’s lymphoma. J Clin Oncol. 2002;20(10):2453–63.

Article  CAS  PubMed  Google Scholar 

TA D. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792–8.

Article  Google Scholar 

Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-ommaya 131-I-3F8. J Clin Oncol. 2007;25(34):5465–70.

Article  PubMed  Google Scholar 

Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97:409–18.

Article  PubMed  Google Scholar 

Larson SM, Carrasquillo JA, Cheung N-KV, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15(6):347–60.

Article  CAS